Enhancing Existing Approaches to Peripheral T-Cell Lymphoma

Foss, Francine M.

doi:10.1053/j.seminhematol.2010.01.012

Cited by 8 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12 Therefore, new treatment regimens are clearly needed for PTCL-NOS, including the addition of novel agents to existing regimens, new regimens combining novel agents, use of monoclonal antibodies, and innovative strategies for stem cell transplantation. [29][30][31][32] We did find that initial radiation therapy improved the survival of patients with stage 1 disease who also received chemotherapy compared with those who received only chemotherapy, similar to the experience with diffuse large B-cell lymphoma. 33,34 However, our study was retrospective in nature and selection bias may have been present.…”

Section: Discussionsupporting

confidence: 71%

“…by guest www.bloodjournal.org From the study was obtained from the Institutional Review Board at the coordinating center (University of Nebraska Medical Center) and at each participating center per the institutional policy. The cases selected for the study were previously untreated patients 19 years of age or older with de novo PTCL or NKTCL, excluding mycosis fungoides and Sézary syndrome, who were diagnosed between January 1, 1990 and December 31,2002. The patients were consecutive from each institution and were required to have adequate tissue biopsies for diagnosis and classification.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project

Weisenburger

Savage

Harris

et al. 2011

Blood

388

354

View full text Add to dashboard Cite

The International Peripheral T-cell Lymphoma Project is a collaborative effort to better understand peripheral T-cell lymphoma (PTCL). A total of 22 institutions submitted clinical and pathologic material on 1314 cases. One objective was toanalyze the clinical and pathologic features of 340 cases of PTCL, not otherwise specified. The median age of the patients was 60 years, and the majority (69%) presented with advanced stage disease. Most patients (87%) presented with nodal disease, but extranodal disease was present in 62%. The 5-year overall survival was 32%, and the 5-year failure-free survival was only 20%. The majority of patients (80%) were treated with combination chemotherapy that included an anthracycline, but there was no survival advantage. The International Prognostic Index (IPI) was predictive of both overall survival and failure-free survival (P < .001). Multivariate analysis of clinical and pathologic prognostic factors, respectively, when controlling for the IPI, identified bulky disease (> 10 cm), thrombocytopenia (< 150 ؋ 10 9 /L), and a high number of transformed tumor cells (> 70%) as adverse predictors of survival, but only the latter was significant in final analysis. Thus, the IPI and a single pathologic feature could be used to stratify patients with PTCL-not otherwise specified for novel and risk-adapted therapies. (Blood. 2011;117(12):3402-3408) IntroductionPeripheral T-cell lymphoma (PTCL) and natural killer/T-cell lymphoma (NKTCL) are an uncommon and heterogeneous group of disorders that compose 5% to 20% of all non-Hodgkin lymphomas (NHLs) in different parts of the world. 1,2 In recent years, the incidence of PTCL and NKTCL in the United States has increased by almost 3-fold with an annual increase of 3.8%, whereas the incidence of B-cell lymphoma and Hodgkin lymphoma has been relatively stable. 3,4 One of the most common subtypes of PTCL is a heterogeneous group of nodal and extranodal mature T-cell lymphomas that do not correspond to any of the specifically defined T-cell entities in the World Health Organization classification, 1 and are therefore called PTCL, not otherwise specified (NOS). Uncommon variants of PTCL-NOS include lymphoepithelioid (Lennert) lymphoma, and cases with a follicular or T-zone pattern of growth. 1 Over the last 12 years, several clinical studies have attempted to identify the clinical and pathologic features of prognostic importance in PTCL-NOS, but the number of cases in these studies was generally small and the findings have been inconsistent or unconfirmed. [5][6][7][8][9][10][11][12][13] The International Peripheral T-cell Lymphoma Project was undertaken as a large retrospective study of PTCL and NKTCL in North America, Europe, and Asia with the goal of better characterizing this group of NHL. One objective of was to analyze the clinical and pathologic features of the 340 cases of PTCL-NOS in the study, and to determine the important prognostic factors for this uncommon entity. MethodsTwenty-two institutions in North America, Europe, and Asia partici...

show abstract

Section: Discussionsupporting

confidence: 71%

mentioning

confidence: 99%

Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project

Weisenburger

Savage

Harris

et al. 2011

Blood

388

354

View full text Add to dashboard Cite

show abstract

“…9,10 However, the treatment of advanced-stage MF is still a challenge, despite new biologic and targeted therapies and particularly in view of the short duration of response (DOR). 11 Systemic polychemotherapy is widely used. 10 Although response rates (RRs) are high in uncontrolled monocentric studies (from 55% up to 81%), 9 remissions are invariably short lived.…”

Section: Journal Of Clinical Oncologymentioning

confidence: 99%

Prospective International Multicenter Phase II Trial of Intravenous Pegylated Liposomal Doxorubicin Monochemotherapy in Patients With Stage IIB, IVA, or IVB Advanced Mycosis Fungoides: Final Results From EORTC 21012

Dummer

Quaglino

Becker

et al. 2012

JCO

View full text Add to dashboard Cite

PURPOSE: Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma.There is a need for multicenter trials involving defined patient populations using rigorous assessment criteria. We have investigated pegylated liposomal doxorubicin (PLD) in a clearly defined patient population with advanced MF. PATIENTS AND METHODS: Eligible patients had stage IIB, IVA, or IVB MF, refractory or recurrent after at least two previous systemic therapies. Patients were registered to receive a maximum of six cycles of PLD 20 mg/m2 on days 1 and 15, every 28 days (one cycle). The primary end point was response rate (RR). RESULTS: Nine centers recruited 49 eligible patients. The median number of chemotherapy cycles received was five. There were no grade 3 to 4 hematologic toxicities. Grade 3 or 4 nonhematologic/nonbiochemical toxicities included cardiac symptom (2%), allergy/hypersensitivity (2%), constitutional symptom (4%), hand and foot reaction (2%), other dermatologic toxicity (6%), other GI toxicity (4%), infection (4%), pulmonary embolism (2%), and cardiac ischemia (2%). Of 49 patients, 20 (40.8%) were responders (complete clinical response [CCR] or partial response [PR] as overall response): three (6.1%) experienced CCRs, and 17 (34.7%) experienced PRs. A 50% or greater reduction of cutaneous manifestations was observed in 26 (60.5%) of 43 assessable patients. Two early deaths were reported, resulting from related cardiovascular toxicity and disease progression. The lower limit of the one-sided 90% CI for RR was 31.2%. Median time to progression and median duration of response were 7.4 and 6 months, respectively. CONCLUSION: PLD has an acceptable safety profile in patients with advanced MF. The efficacy of PLD seems promising. A B S T R A C T PurposeMycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma. There is a need for multicenter trials involving defined patient populations using rigorous assessment criteria. We have investigated pegylated liposomal doxorubicin (PLD) in a clearly defined patient population with advanced MF. Patients and MethodsEligible patients had stage IIB, IVA, or IVB MF, refractory or recurrent after at least two previous systemic therapies. Patients were registered to receive a maximum of six cycles of PLD 20 mg/m 2 on days 1 and 15, every 28 days (one cycle). The primary end point was response rate (RR). ResultsNine centers recruited 49 eligible patients. The median number of chemotherapy cycles received was five. There were no grade 3 to 4 hematologic toxicities. Grade 3 or 4 nonhematologic/ nonbiochemical toxicities included cardiac symptom (2%), allergy/hypersensitivity (2%), constitutional symptom (4%), hand and foot reaction (2%), other dermatologic toxicity (6%), other GI toxicity (4%), infection (4%), pulmonary embolism (2%), and cardiac ischemia (2%). Of 49 patients, 20 (40.8%) were responders (complete clinical response [CCR] or partial response [PR] as overall response): three (6.1%) experienced CCRs, and 17 (34.7%) experienced PRs. A...

show abstract

“…A number of more novel agents have been investigated in PTCL but most data, as expected, is in relapsed/refractory disease (Foss, 2010).…”

Section: Nodal Ptclmentioning

confidence: 99%

Guidelines for the management of mature T‐cell and NK‐cell neoplasms (excluding cutaneous T‐cell lymphoma)

Dearden

Johnson

Pettengell³

et al. 2011

Br J Haematol

101

View full text Add to dashboard Cite

SummaryThe peripheral T-cell neoplasms are a biologically and clinically heterogeneous group of rare disorders that result from clonal proliferation of mature post-thymic lymphocytes. Natural killer (NK) cell neoplasms are included in this group. The World Health Organization classification of haemopoietic malignancies has divided this group of disorders into those with predominantly leukaemic (disseminated), nodal, extranodal or cutaneous presentation. They usually affect adults and are more commonly reported in males than in females. The median age at diagnosis is 61 years with a range of 17-90 years. Although some subtypes may follow a relatively benign protracted course most have an aggressive clinical behaviour and poor prognosis. Excluding anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL), which has a good outcome, 5-year survival for other nodal and extranodal T-cell lymphomas is about 30%. Most patients present with unfavourable international prognostic index scores (>3) and poor performance status. The rarity of these diseases and the lack of randomized trials mean that there is no consensus about optimal therapy for T-and NK-cell neoplasms and recommendations in this guideline are therefore based on small case series, phase II trials and expert opinion.

show abstract

Enhancing Existing Approaches to Peripheral T-Cell Lymphoma

Cited by 8 publications

References 21 publications

Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project

Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project

Prospective International Multicenter Phase II Trial of Intravenous Pegylated Liposomal Doxorubicin Monochemotherapy in Patients With Stage IIB, IVA, or IVB Advanced Mycosis Fungoides: Final Results From EORTC 21012

Guidelines for the management of mature T‐cell and NK‐cell neoplasms (excluding cutaneous T‐cell lymphoma)

Contact Info

Product

Resources

About